Brentuximab vedotin (SGN-35) is currently being evaluated in multiple clinical trials, including a phase II clinical trial for patients with relapsed or refractory systemic ALCL, and a phase II trial for patients who have previously participated in a brentuximab vedotin study.

For more information about brentuximab vedotin, click on the link to the left. You may also click on the link below to go directly to the clinicaltrials.gov web site for more details about these clinical trials.

A phase 2 open label trial of SGN-35 for patients who have previously participated in an SGN-35 study

A phase II open label trial of SGN-35 for systemic anaplastic large cell lymphoma (enrollment complete)

For general information about clinical trials, click on the About Clinical Trials page to the left.